JP Morgan initiated coverage on Blueprint Medicines Corporation BPMC, a biotech company focused on modulating immune mast cells.In 2023, the FDA approved Blueprint Medicines’ Ayvakit (avapritinib) as the first, only treatment for indolent systemic mastocytosis (ISM).In the third quarter of 2024, Ayvakit reported net product revenues of $128.2 million, including $113.1 million in the U.S. and $15.1 million ex-U.S., representing 136% growth year over year.Blueprint Medicines anticipates approximately $475 mil ...